The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2022 | The promise of elranatamab and other bispecifics in the treatment of myeloma
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, shares some insights into the promise of bispecific antibodies, such as elranatamab, for the treatment of triple-class refractory myeloma patients. Dr Ramasamy highlights the promise that these agents have shown in clinical trials, and the importance of further investigating and better understanding how to manage the side effects of bispecific antibodies. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
